Abstract | INTRODUCTION: PATIENTS AND METHODS: Eligible patients had stage IIIB or IV NSCLC after 1 previous line of chemotherapy and an Eastern Cooperative Oncology Group performance status of 0 to 2. Three dose levels (DLs) of lapatinib (daily)/ pemetrexed (every 21 days) were evaluated: DL0, 1250 mg/400 mg; DL1, 1250 mg/500 mg; and DL2, 1500 mg/500 mg, respectively. The primary outcome was identification of the optimal treatment regimen. RESULTS: Eighteen patients were treated (DL0: n = 4; DL1: n = 8; DL2: n = 6). The most common adverse events (any grade) were diarrhea (61%), rash (44%), nausea (33%), anemia, and fatigue (both 28%). DL1 was determined as optimal after 3 dose-limiting toxicities (DLTs) during the first cycle of DL2 (Grade 3 diarrhea and mucositis, Grade 4 lymphocytopenia); no other DLTs were observed. Partial response was detected in 4 patients. cfTSmRNA was at the limit of detection and was not measurable in all patients. Nonsignificant trends were observed, suggesting that higher levels of cfTSmRNA are associated with poorer outcome. Confirmatory studies are required. CONCLUSION:
|
Authors | Rodryg Ramlau, Michael Thomas, Silvia Novello, Ruth Plummer, Martin Reck, Tomomi Kaneko, Mike R Lau, Jane Margetts, John Lunec, Joyce Nutt, Giorgio V Scagliotti |
Journal | Clinical lung cancer
(Clin Lung Cancer)
Vol. 16
Issue 5
Pg. 348-57
(Sep 2015)
ISSN: 1938-0690 [Electronic] United States |
PMID | 25700774
(Publication Type: Clinical Trial, Phase I, Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2015 Elsevier Inc. All rights reserved. |
Chemical References |
- Biomarkers, Tumor
- Quinazolines
- Pemetrexed
- Lapatinib
- Thymidylate Synthase
|
Topics |
- Aged
- Antineoplastic Combined Chemotherapy Protocols
(administration & dosage, adverse effects, therapeutic use)
- Biomarkers, Tumor
(genetics)
- Carcinoma, Non-Small-Cell Lung
(drug therapy, genetics, pathology)
- Dose-Response Relationship, Drug
- Female
- Humans
- Lapatinib
- Lung Neoplasms
(drug therapy, genetics, pathology)
- Male
- Middle Aged
- Neoplasm Metastasis
- Pemetrexed
(administration & dosage)
- Quinazolines
(administration & dosage)
- Thymidylate Synthase
(genetics)
- Treatment Outcome
|